Koichi Sugihara Selected Research

Koichi Sugihara Research Topics

2	Systemic Lupus Erythematosus (Libman-Sacks Disease) 01/2022 - 01/2022
1	Rheumatic Diseases (Rheumatism) 07/2022
1	COVID-19 07/2022
1	Oral Ulcer (Mouth Ulcer) 01/2022
1	Premature Birth (Birth, Premature) 01/2022
1	Juvenile Arthritis (Juvenile Idiopathic Arthritis) 09/2021
1	Interstitial Lung Diseases (Interstitial Lung Disease) 09/2021
1	Churg-Strauss Syndrome (Allergic Angiitis) 01/2021
1	Otitis Media 01/2021
1	Vasculitis (Vasculitides) 12/2020
1	Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis 12/2020
1	Infections 12/2020
1	Inflammation (Inflammations) 12/2020
1	Glomerulonephritis 12/2020
1	Nontuberculous Mycobacterium Infections 12/2020
1	Nephritis 12/2020
1	Fever (Fevers) 12/2020
1	Endarteritis 12/2020
1	Communicable Diseases (Infectious Diseases) 12/2020

2	Immunoglobulin G (IgG)IBA 07/2022 - 12/2020
2	Interleukin-6 (Interleukin 6)IBA 01/2022 - 09/2021
2	Immunosuppressive Agents (Immunosuppressants)IBA 01/2022 - 01/2021
2	CytokinesIBA 01/2022 - 01/2022
1	COVID-19 VaccinesIBA 07/2022
1	mRNA VaccinesIBA 07/2022
1	BNT162 VaccineIBA 07/2022
1	Proteins (Proteins, Gene)FDA Link 07/2022
1	Messenger RNA (mRNA)IBA 07/2022
1	RNA (Ribonucleic Acid)IBA 07/2022
1	Immunoglobulin M (IgM)IBA 07/2022
1	SARS-CoV-2 spike proteinIBA 07/2022
1	Interleukin-10 (Interleukin 10)IBA 01/2022
1	apremilastIBA 01/2022
1	GlucocorticoidsIBA 01/2022
1	Hydroxychloroquine (Plaquenil)FDA LinkGeneric 01/2022
1	tocilizumab (atlizumab)FDA Link 09/2021
1	mepolizumabIBA 01/2021
1	InterleukinsIBA 01/2021
1	AntibodiesIBA 12/2020
1	antiglomerular basement membrane antibodyIBA 12/2020
1	Antineutrophil Cytoplasmic Antibodies (ANCA)IBA 12/2020

2	Therapeutics 01/2022 - 01/2021